Clinical trials of GSK1070806 or the IL18BP antagonist (tadekinig alfa) in IBD and monogenic IL-18-driven autoinflammatory diseases such as sJIA and AOSD should provide further evidence for targeting IL-18 in IL-18opathies [24,25]. This evidence concerns the gene IL18BP and systemic-onset juvenile idiopathic arthritis.